AXSM

Business Context and Reporting Period

Axsome Therapeutics, Inc. (AXSM) is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) conditions. This Form 10-Q covers the quarterly period ended June 30, 2026. The company currently commercializes three FDA-approved products: AUVELITY (for major depressive disorder and agitation associated with dementia due to Alzheimer's disease), SUNOSI (for excessive daytime sleepiness), and SYMBRAVO (for acute migraine). The company maintains a pipeline of novel product candidates, including AXS-12 (narcolepsy), AXS-14 (fibromyalgia), and recently acquired assets AXS-17 (epilepsy) and AXS-20 (schizophrenia).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 45.5% year-over-year for the three months ended June 30, 2026 ($218.4M vs. $150.0M) and 50.9% for the six-month period ($409.6M vs. $271.5M). This growth was driven by increased unit sales of AUVELITY and SUNOSI, and the commercial launch of SYMBRAVO in June 2025.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose significantly to $208.1M (Q2 2026) from $130.3M (Q2 2025), primarily due to pre-launch activities for the new AUVELITY indication (AADDAD), expanded sales force, and national direct-to-consumer advertising.
• Net Loss Expansion: Net loss increased to $51.3M for Q2 2026 from $48.0M in Q2 2025, reflecting the substantial increase in commercialization costs outpacing revenue growth.
• Debt Restructuring: The company repaid its prior Hercules Loan Agreement in May 2025 using proceeds from a new Blackstone Loan Agreement. As of June 30, 2026, the company holds $120.0M in term loans and $70.0M in revolver borrowings (repaid in July 2026).

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash resources ($319.9M as of June 30, 2026) are sufficient to fund operations for at least twelve months. The company expects expenses to increase further due to ongoing commercialization and pipeline development.
• Product Launches: The company initiated the commercial launch of AUVELITY for agitation associated with dementia due to Alzheimer's disease (AADDAD) in June 2026 following FDA approval in April 2026.
• Pipeline Progress: The FDA accepted the New Drug Application (NDA) for AXS-12 (narcolepsy) for filing in July 2026, with a PDUFA target action date of May 1, 2027. The company is advancing Phase 3 trials for solriamfetol in ADHD, binge eating disorder, and shift work disorder.
• Risks: Key risks include the company's history of losses and accumulated deficit of $1.42B, dependence on the commercial success of a limited product portfolio, potential generic competition (though patent litigation settlements for SUNOSI extend exclusivity to 2040), and regulatory uncertainties regarding drug pricing and reimbursement (e.g., Inflation Reduction Act).

Investor Verification Checklist

• Commercial Execution: Verify the uptake of AUVELITY for the new AADDAD indication launched in June 2026 and the sustainability of SG&A expense growth relative to revenue.
• Debt Covenants: Review the Blackstone Loan Agreement covenants, specifically the minimum liquidity covenant of $30.0M, to ensure compliance given the company's burn rate.
• Patent Litigation Status: Confirm the status of the ongoing patent infringement lawsuit against Apotex regarding SYMBRAVO, as a generic launch could materially impact future revenues.
• Regulatory Milestones: Monitor the FDA review timeline for the AXS-12 NDA (PDUFA date: May 1, 2027) and the initiation of Phase 3 trials for other pipeline assets.
• Related Party Transactions: Note the 3.0% royalty obligation to Antecip (owned by the CEO) on AUVELITY net sales, which impacts gross margins.